Clinical Trial Update: A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND) [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating nusinersen in children with spinal muscular atrophy who previously received onasemnogene abeparvovec has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Spinraza (nusinersen)

Snippet

Sponsor: Biogen | Conditions: Muscular Atrophy, Spinal | Phase 4 | Status: COMPLETED